Coherus Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
Coherus Oncology, Inc. (CHRS) filed this Current Report on Form 8-K on February 12, 2026, to disclose a significant capital raising event. The company is incorporated in Delaware and trades on The Nasdaq Global Market.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Issued: 28,600,000 shares of Common Stock (Firm Shares).
- Optional Shares: Underwriters granted an option to purchase up to 4,290,000 additional shares to cover over-allotments.
- Offering Price: $1.75 per share to the public.
- Price to Company: $1.645 per share (after underwriting discounts).
- Net Proceeds: Approximately $47.0 million (after underwriting discounts and commissions, before estimated offering expenses).
- Closing Date: February 17, 2026.
Material Changes and Liquidity Impact
The primary material change is the increase in the company's cash position due to the completion of the offering. The filing does not provide comparative financial metrics (revenue, profit, or margins) for the prior period as this is a transactional report rather than a periodic financial statement. The transaction significantly alters the company's capital structure by increasing outstanding share count and liquidity.
Management Commentary, Risks, and Contingencies
- Lock-Up Agreement: The Company, its directors, executive officers, and certain affiliated stockholders agreed not to sell or transfer any Common Stock for 60 days following February 12, 2026, without written consent from the Representatives.
- Underwriters: TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. served as representatives.
- Legal Opinions: An opinion regarding the validity of the securities was provided by Latham & Watkins LLP.
- Risks: The filing notes that the Underwriting Agreement contains customary representations, warranties, and indemnification obligations, which are subject to limitations agreed upon by the parties.
Key Facts for Investor Verification
- Verify the final number of shares issued if the over-allotment option is exercised.
- Confirm the total estimated offering expenses to calculate the final net proceeds.
- Review the updated share count and diluted earnings per share impact in subsequent filings.
- Monitor the 60-day lock-up expiration date (approximately April 13, 2026) for potential selling pressure.